Windlas Biotech Limited has announced the inauguration of its state-of-the-art injectable facility for the production of Small Volume Parenteral products, designed to adhere to international cGMP standards.
Following a joint inspection conducted by the Central Drugs Standard Control Organisation and the State Licensing Authority of Uttarakhand, the company has obtained a manufacturing license from the Drug Controlling & Licensing Authority of Uttarakhand. The facility has commenced the production of commercial batches, with plans to introduce several new products throughout the Financial Year 2025.
This milestone underscores the company’s ongoing commitment to developing and manufacturing complex dosage forms such as Ampoules, Liquid Vials, and Lyophilized Vials, thus expanding its product portfolio to encompass critical care and other specialized therapeutic segments. The Injectable plant will serve all three of Windlas Biotech’s business verticals: CDMO, Trade Generics & Institutional, and Exports.
Mr. Hitesh Windlass, Managing Director of Windlas Biotech, commented on this achievement, stating, “The commissioning of our injectable facility is a significant milestone, reflecting our dedication to delivering advanced and life-saving treatments to the market. This facility not only enhances our manufacturing capabilities in a new dosage format but also underscores our commitment to excellence and innovation in pharmaceutical manufacturing. We are well-positioned to meet the evolving needs of our valued customers and strengthen our position as a leader in the industry. We remain steadfast in upholding high standards of quality, compliance, and customer satisfaction as we continue to drive innovation and growth in the pharmaceutical sector.”